Obinutuzumab: Clinical Trials

62 actively recruiting trials across 32 locations

Also known as: Anti-CD20 Monoclonal Antibody R715, Anti-CD20 Monoclonal Antibody R7159, GA 101, GA-101, GA101, Gazyva, Gazyvaro, Gazyvaro®, R 7159, R-7159, R7159, RO 5072759, RO-5072759, RO5072759, RO5072759, GA101, GAZYVA, GAZYVARO, RO5072759, GA101, Gazyva®, Gazyvaro™, huMAB(CD20), huMAb <CD20>

Filter by location:

Other12 trials

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Phase 1

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

Phase 2

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Phase 3

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

N/A

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Phase 2

Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

Phase 2

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Phase 2

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Phase 3

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

Houston, Texas6 trials

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

MD Anderson Cancer Center

Phase 2

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

M D Anderson Cancer Center

Phase 2

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M D Anderson Cancer Center

Phase 2

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

M D Anderson Cancer Center

Phase 2

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

MD Anderson Cancer Center

Phase 2

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

M D Anderson Cancer Center

Phase 2

Boston, Massachusetts4 trials

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Dana Farber Cancer Institute (Data Collection and Specimen Analysis)

Phase 1

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Dana Farber Cancer Institute

Phase 2

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Massachusetts General Hospital Cancer Center

Phase 2

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

Massachusetts General Hospital

Phase 2

Duarte, California3 trials

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center

Phase 2

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

City of Hope Medical Center

Phase 2

Fresno, California3 trials

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Ucsf Fresno University of California San Francisco Fresno

Phase 3

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

University of California, San Francisco (UCSF) Fresno

Phase 2

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

UCSF Fresno /ID# 264712

Phase 3

Birmingham, Alabama2 trials

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Children's Hospital of Alabama

Phase 1/2

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

University of Alabama at Birmingham Cancer Center

Phase 3

Tucson, Arizona2 trials

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Arizona Oncology - Tucson - Rudasill /ID# 267552

Phase 3

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Banner University Medical Center - Tucson

Phase 2

La Jolla, California2 trials

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

UC San Diego Moores Cancer Center

Phase 1

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Moores Cancer Center at UC San Diego /ID# 230157

Phase 2

Atlanta, Georgia2 trials

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Emory University Hospital/Winship Cancer Institute

Phase 2

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Winship Cancer Institute at Emory University

Phase 2

Bethesda, Maryland2 trials

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

National Institutes of Health Clinical Center

Phase 1/2

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

National Institutes of Health Clinical Center

Phase 1

Portland, Oregon2 trials

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

OHSU Knight Cancer Institute

Phase 1/2

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

OHSU Knight Cancer Institute

Phase 1

Anchorage, Alaska1 trial

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Alaska Oncology & Hematology, LLC

Phase 2

Phoenix, Arizona1 trial

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Mayo Clinic Phoenix

Phase 1/2

Scottsdale, Arizona1 trial

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic in Arizona

Phase 2

Berkeley, California1 trial

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Alta Bates Summit Medical Center

Phase 3

Clovis, California1 trial

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

University of California San Francisco - Fresno Center for Medical Education and Research

Phase 1

Davis, California1 trial

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

University of California, Davis

Phase 2

Laguna Hills, California1 trial

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Uci Health Laguna Hills

Phase 3

Loma Linda, California1 trial

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Loma Linda University health

Phase 2

San Francisco, California1 trial

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program

Phase 1

Orlando, Florida1 trial

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

AdventHealth Orlando

Phase 1

Chicago, Illinois1 trial

Avo In R/R And Previously Untreated MCL

University of Chicago Medical Center

Phase 1/2

Evanston, Illinois1 trial

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Northwestern University

Phase 2

Harvey, Illinois1 trial

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Ingalls Memorial Hospital

Phase 1/2

Scarborough, Maine1 trial

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

New England Cancer Specialists

Phase 2

Baltimore, Maryland1 trial

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Phase 2

Omaha, Nebraska1 trial

CAR-T Followed by Bispecific Antibodies

University of Nebraska Medical Center

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Valhalla, New York1 trial

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

New York Medical College

Phase 2

Cincinnati, Ohio1 trial

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

University of Cincinnati Medical Center

Phase 2

Cleveland, Ohio1 trial

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute

Phase 1

Columbus, Ohio1 trial

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 2

Salt Lake City, Utah1 trial

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Huntsman Cancer Institute at University of Uta

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.